Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma

INTRODUCTION: For patients with eosinophilic asthma with allergic characteristics, understanding the key drivers of exacerbations is important to identify optimal treatment strategies. Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody that significantly reduces e...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, David J., Humbert, Marc, Hirsch, Ian, Newbold, Paul, Garcia Gil, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004419/
https://www.ncbi.nlm.nih.gov/pubmed/31836949
http://dx.doi.org/10.1007/s12325-019-01191-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004419/
https://www.ncbi.nlm.nih.gov/pubmed/31836949
http://dx.doi.org/10.1007/s12325-019-01191-2

Ejemplares similares